Fiscal Year Ending October 2026 Q3 Financial Results Summary [Japanese GAAP] (Non-Consolidated)

Overview of performance

In the third quarter financial results for the fiscal year ending October 2026, following the absorption of Hybrid Medical Co., Ltd., disclosures will be on a standalone basis. For the cumulative third quarter, net sales were 2,567,467 thousand yen, operating income was 179,232 thousand yen, ordinary income was 174,171 thousand yen, and quarterly net income was 174,484 thousand yen. The segment is a single segment focused on regenerative medicine. It explains the trend in the number of partner medical institutions and processing contracts. Recently, cost reduction and resource optimization have continued. Joint development of new processing technologies is advancing as well.

Financial position and outlook

In terms of financial position, total assets stood at 6,945,203 thousand yen and net assets at 6,067,369 thousand yen, with net assets increasing year over year due to retained earnings from the absorption. The full-year earnings guidance for the fiscal year ending October 2026 has been revised and announced: net sales of 3,367 million yen, operating income of 82 million yen, ordinary income of 76 million yen, net income attributable to owners of the parent of negative 124 million yen, and basic earnings per share of negative 6.26 yen. Note that the results summary indicates uncertainty in forward-looking projections.